CBDYOTC

Target Group Inc.

Healthcare·Immunology·Commercial·Hamilton, ON, Canada
Immunology

Target Group Inc. (CBDY): 16 pipeline candidates · ~29 mo cash runway · 2 clinical trials. Updated within the last hour.

9.3/10

BioSniper Score

3-factor signal · derived from public data

Cash Runway7.9

28.5 months

Financial Health10.0

D/E -1.71 · 0% dilution

Pipeline MaturityN/A

N/A

Pipeline Breadth10.0

16 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for Target Group Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$926K

Cash

$210K

Quarterly Burn

$94K

Runway

28.5 mo

Revenue

$879K

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Nov 2028
Today~31 mo out
Catalyst within runway

Pipeline (16 candidates)

Showing 10 of 16 candidates. Sign up for full pipeline.

2 clinical trials·CEO: Mr. Anthony Carlo Zarcone

Frequently asked questions

How many drug candidates are in Target Group Inc.'s pipeline?

Target Group Inc. (CBDY) has 16 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is Target Group Inc.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, Target Group Inc. has approximately 28.5 months of cash runway.

What is Target Group Inc.'s market capitalization?

Target Group Inc.'s market capitalization is approximately $926K.

Who is the CEO of Target Group Inc.?

Mr. Anthony Carlo Zarcone is the chief executive officer of Target Group Inc. (CBDY).

Get the full picture on Target Group Inc.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.